Natives Engaged in Alzheimers Research - 'Ike Kupuna (NEAR)

July 30, 2024 updated by: University of Hawaii

Natives Engaged in Alzheimers Research - 'Ike Kupuna (Elder Wisdom) Project

This study will conduct a group randomized trial to test the effects of a hula-based intervention in improving vascular risk factors for ADRD and cognitive complaints and function over 12 months.

Study Overview

Detailed Description

This study will conduct a pragmatic group-randomized trial (GRT) with NHPIs aged 50-75 years with at least 1 of 4 modifiable vascular risk factors for ADRD (hypertension, hyperglycemia, obesity, or dyslipidemia) and either SCI or MCI using a wait-list control design to test the effects of the hula-based intervention. The primary outcomes will be vascular risk factors for ADRD and subjective cognitive complaints. Secondary outcomes will include measures of cognitive performance, physical function, and mental health.

Study Type

Interventional

Enrollment (Estimated)

192

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Hawaii
      • Honolulu, Hawaii, United States, 96813
        • Recruiting
        • Kula No Na Po'e
        • Contact:
      • Honolulu, Hawaii, United States, 96819
        • Recruiting
        • Kokua Kalihi Valley
        • Contact:
      • Wailuku, Hawaii, United States, 96793
        • Recruiting
        • Hui No Ke Ola Pono
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. self-reported Native Hawaiian or other Pacific Islander ancestry;
  2. ages 50+ but not older than 75 (optimal age range for preventing future dementia in people with cognitive impairment, above 75 is not likely to benefit from this study given their advance age);
  3. has subjective cognitive impairment (SCI) or mild cognitive impairment (MCI);
  4. have a diagnosis of hypertension, diabetes, dyslipidemia, or obesity (body-mass-index ≥ 30 kg/m2);
  5. physically able and willing to engage in moderate physical activity necessary for Hula; and
  6. physician's approval to participate in moderate physical activity

Exclusion Criteria:

  1. currently pregnant;
  2. already actively practicing Hula at least once per week; or
  3. clinical diagnosis of ADRD (mild to severe); or
  4. current diagnosed major depressive disorder at moderate or greater stage, or moderate or greater depression on the Center for Epidemiological Studies Depression Scale (CES-D).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
The intervention group will immediately receive the Ola Mau i ka Hula intervention after randomization for 12 months. The intervention program is 8 months with a 4 month self-monitoring period.

The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons.

These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network.

For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly.

Other Names:
  • Ola Mau
No Intervention: Wait-list control group

After baseline data collection, participants randomized to the wait-list control arm will not receive the Ola Mau i ka Hula Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not be offered the intervention until after the intervention arm is completed and their 12-month follow-up data collection is completed. They will only receive the educational component of the intervention from us during this 12-month period but they will be instructed to continue with their routine medical care as usual.

Wait-list control group will be offered the opportunity to receive intervention at the conclusion of 12 month assessment period, regardless of whether they were retained for the full 12 months of data collection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in participants' systolic blood pressure at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
Vascular risk factor assessed using Omron©HEM-907XL
3 months, 8 months, 12 months
Change in participants' Hemoglobin A1c at each time frame from baseline
Time Frame: 12 months
Vascular risk factor assessed using Alere Cholestech LDX® System
12 months
Change in participants' total cholesterol at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
Vascular risk factor assessed using Alere Cholestech LDX® System
3 months, 8 months, 12 months
Change in participants' body mass index at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
Vascular risk factor assessed using Tanita BWB800AS scale
3 months, 8 months, 12 months
Change in participants' Cognitive Change Index score at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
Cognitive function assessed using Cognitive Change Index assessment
3 months, 8 months, 12 months
Change in participants' Number Symbol Coding Test score at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
Cognitive function assessed using Number Symbol Coding Test
3 months, 8 months, 12 months
Change in participants' overall Cognivue score at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
Cognitive function assessed using Cognivue device
3 months, 8 months, 12 months
Change in participants' overall Quick Dementia Rating System score at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
Cognitive function assessed using Quick Dementia Rating System assessment
3 months, 8 months, 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Joseph K Kaholokula, PhD, University of Hawaii

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 15, 2022

Primary Completion (Estimated)

June 15, 2025

Study Completion (Estimated)

April 30, 2027

Study Registration Dates

First Submitted

August 12, 2022

First Submitted That Met QC Criteria

September 7, 2022

First Posted (Actual)

September 9, 2022

Study Record Updates

Last Update Posted (Actual)

August 1, 2024

Last Update Submitted That Met QC Criteria

July 30, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Cognitive Impairment

Subscribe